Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAJ Bell Regulatory News (AJB)

Share Price Information for AJ Bell (AJB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 311.50
Bid: 310.50
Ask: 311.50
Change: 2.00 (0.65%)
Spread: 1.00 (0.322%)
Open: 306.00
High: 312.00
Low: 306.00
Prev. Close: 309.50
AJB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hardman & Co Research: AJ Bell (AJB): Platform for growth

24 Jan 2019 07:15

Hardman & Co Research Hardman & Co Research: AJ Bell (AJB): Platform for growth 24-Jan-2019 / 07:15 GMT/BST


Hardman & Co Research: Platform for growth

AJ Bell is one of the largest and fastest-growing investment platforms in the UK. It serves both the adviser market and the DIY investor. Having transitioned to updated technology in 2014, it is well placed to ride the growth in the market and pick up disaffected clients from competitor platforms that are only now upgrading. We anticipate strong profit growth on the back of higher revenues and positive operational gearing. The new asset management business should add further momentum, and higher UK savings rates could be the icing on the cake.

Please click here for the full report:

https://www.hardmanandco.com/research/corporate-research/platform-for-growth-2/

To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.comFollow us on Twitter @HardmanandCo Contact: Jason Streets +44 20 7194 7622 js@hardmanandco.com

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

769003 24-Jan-2019 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
18th Apr 20247:00 amRNSQ2 Trading Update
15th Apr 20243:53 pmRNSDirector/PDMR Shareholding
10th Apr 20248:21 amRNSDirector/PDMR Shareholding
28th Mar 20249:45 amRNSDirectorate Change
13th Mar 20243:30 pmRNSDirector/PDMR Shareholding
4th Mar 20243:44 pmRNSDirector/PDMR Shareholding
14th Feb 20248:28 amRNSDirector/PDMR Shareholding
9th Feb 20243:03 pmRNSDirector/PDMR Shareholding
1st Feb 20247:57 amRNSIssue of Ordinary Shares & Total Voting Rights
30th Jan 20242:56 pmRNSResult of AGM
29th Jan 20249:32 amRNSDirector/PDMR Shareholding
22nd Jan 20244:51 pmRNSHolding(s) in Company
18th Jan 20247:00 amRNSQ1 Trading Update
15th Jan 20249:31 amRNSDirector/PDMR Shareholding
10th Jan 202412:41 pmRNSDirector/PDMR Shareholding
9th Jan 20249:15 amRNSDirector/PDMR Shareholding
2nd Jan 202410:40 amRNSIssue of Ordinary Shares & Total Voting Rights
27th Dec 20234:40 pmRNSDirector/PDMR Shareholding
22nd Dec 202310:17 amRNSNotice of AGM
22nd Dec 20238:24 amRNSBlock Listing Six Monthly Review
19th Dec 20233:41 pmRNSDirector/PDMR Shareholding
18th Dec 20233:46 pmRNSIssue of Ordinary Shares & Total Voting Rights
18th Dec 20233:32 pmRNSDirector/PDMR Shareholding
13th Dec 20234:11 pmRNSDirector/PDMR Shareholding
13th Dec 202312:22 pmRNSDirector/PDMR Shareholding
12th Dec 20231:33 pmRNSStatement re pricing changes
8th Dec 20232:22 pmRNSDirector/PDMR Shareholding
8th Dec 20232:21 pmRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSChange of Auditor
7th Dec 20237:00 amRNSFinal Results
4th Dec 20237:00 amRNSAppointment of Non-Executive Director
14th Nov 20232:02 pmRNSDirector/PDMR Shareholding
19th Oct 20237:53 amRNSHolding(s) in Company
19th Oct 20237:00 amRNSYear-end Trading Update
13th Oct 20239:36 amRNSDirector/PDMR Shareholding
29th Sep 20237:48 amRNSDirector/PDMR Shareholding
28th Sep 20234:25 pmRNSDirector/PDMR Shareholding
14th Sep 20234:41 pmRNSDirector/PDMR Shareholding
13th Sep 20237:39 amRNSDirector/PDMR Shareholding
29th Aug 20239:02 amRNSDirector/PDMR Shareholding
22nd Aug 20237:49 amRNSDirector/PDMR Shareholding
15th Aug 20239:17 amRNSDirector/PDMR Shareholding
20th Jul 20237:00 amRNSQ3 Trading Update
13th Jul 20234:01 pmRNSDirector/PDMR Shareholding
13th Jul 202311:35 amRNSAppointment of Non-Executive Director
26th Jun 202312:25 pmRNSDirector/PDMR Shareholding
23rd Jun 20238:11 amRNSBlock Listing Six Monthly Return
14th Jun 20239:12 amRNSDirector/PDMR Shareholding
26th May 20232:43 pmRNSDirector/PDMR Shareholding
25th May 20237:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.